Destiny Pharma – Neil Clark, CEO (AIM:DEST) One2One Virtual Forum 10th December 2021

Destiny Pharma PLC (Goal:DEST) (Destiny Pharma PLC (Goal:DEST)) is a clinical phase, ground breaking biotechnology business concentrated on the advancement of novel medications that can protect against life-threatening infections. The company’s pipeline has novel microbiome-primarily based biotherapeutics and XF drug clinical assets such as NTCD-M3, a Section 3 prepared treatment for the prevention of C. difficile infection (CDI) recurrence which is the primary result in of healthcare facility acquired infections in the US. Destiny’s pipeline also includes XF-seventy three nasal gel, which has recently done a positive Section 2b clinical demo targeting the prevention of write-up-surgical staphylococcal healthcare facility infections such as MRSA. The business is also co-building SPOR-COV, a novel, biotherapeutic merchandise for the prevention of COVID-19 and other viral respiratory infections.